Drug Profile
Research programme: biotherapeutics - iBio/Caliber Biotherapeutics
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator iBio Inc
- Developer Caliber Biotherapeutics; iBio Inc
- Class Enzymes; Monoclonal antibodies; Proteins; Recombinant fusion proteins; Vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA
- 19 Feb 2013 iBio and Caliber Biotherapeutics' research programme is available for licensing as of 19 Feb 2013. \http://www.caliberbio.com/\ http://ibioinc.com/
- 19 Feb 2013 Early research in Cancer in USA (unspecified route)